Vera Therapeutics Inc.

AI Score

0

Unlock

34.59
-0.18 (-0.52%)
At close: Jan 14, 2025, 3:59 PM
34.59
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 20.02
Market Cap 2.19B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.61
PE Ratio (ttm) -13.25
Forward PE n/a
Analyst Buy
Ask 54.99
Volume 587,480
Avg. Volume (20D) 762,329
Open 34.99
Previous Close 34.77
Day's Range 33.28 - 35.00
52-Week Range 14.20 - 51.61
Beta undefined

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...

Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2021
Employees 82
Stock Exchange NASDAQ
Ticker Symbol VERA

Analyst Forecast

According to 8 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 90.81% from the latest price.

Buy 87.50%
Hold 12.50%
Sell 0.00%
Stock Forecasts
1 day ago · Source
-6.08%
Vera Therapeutics shares are trading lower. The co... Unlock content with Pro Subscription
2 months ago · Source
-9.23%
Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.